| Clinical data | |
|---|---|
| Routes of administration | subcutaneous |
| ATC code |
|
| Pharmacokinetic data | |
| Bioavailability | N/A |
| Identifiers | |
| CAS Number | |
| PubChemCID | |
| ChemSpider |
|
| UNII | |
| KEGG |
|
| Chemical and physical data | |
| Formula | C152H232N40O45 |
| Molar mass | 3339.763 g·mol−1 |
| |
| |
 N Y (what is this?) (verify) | |
Taspoglutide is a formerexperimental drug, aglucagon-like peptide-1 agonist (GLP-1 agonist), that was under investigation for treatment oftype 2 diabetes and being codeveloped byIpsen andRoche.[1][2]
Initially, phase II trials reported it was effective and well tolerated.[3]
Of the eight planned phase III clinical trials of weekly taspoglutide (four againstexenatide,sitagliptin,insulin glargine, andpioglitazone), at least five were active in 2009.[4] Preliminary results in early 2010 were favourable.[5] (At least one of the eight planned phase III trials had not started recruiting by end 2009.[6])
In September 2010 Roche halted Phase III clinical trials due to instances of serious hypersensitivity reactions and gastrointestinal side effects.[7][8]
As of May 2022[update] no new trials have been registered since 2010.[9]
Taspoglutide is the peptide with the sequence His-Aib-Glu-Gly-Thr-Phe-Thr-Ser-Asp-Val-Ser-Ser-Tyr-Leu-Glu-Gly-Gln-Ala-Ala-Lys-Glu-Phe-Ile-Ala-Trp-Leu-Val-Lys-Aib-Arg-NH2, where Aib is2-aminoisobutyric acid (2-methylalanine).
In other words, it is the 8-(2-methylalanine)-35-(2-methylalanine)-36-L-argininamide derivative of the amino acid sequence 7–36 of human glucagon-like peptide I.
 | Thisdrug article relating to thegastrointestinal system is astub. You can help Wikipedia byexpanding it. |